Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Equity: 2020-2025

Historic Return on Equity for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to 0.90%.

  • Foghorn Therapeutics' Return on Equity fell 338.00% to 0.90% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.90%, marking a year-over-year decrease of 338.00%. This contributed to the annual value of 1.41% for FY2024, which is 114.00% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' Return on Equity stood at 0.90%, which was down 19.68% from 1.12% recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Return on Equity ranged from a high of 9.19% in Q1 2023 and a low of -8.91% during Q4 2022.
  • Over the past 3 years, Foghorn Therapeutics' median Return on Equity value was 1.55% (recorded in 2024), while the average stood at 2.59%.
  • Its Return on Equity has fluctuated over the past 5 years, first skyrocketed by 1,044bps in 2023, then tumbled by 813bps in 2024.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Return on Equity stood at -1.15% in 2021, then tumbled by 776bps to -8.91% in 2022, then surged by 1,037bps to 1.46% in 2023, then soared by 88bps to 2.35% in 2024, then slumped by 338bps to 0.90% in 2025.
  • Its Return on Equity stands at 0.90% for Q3 2025, versus 1.12% for Q2 2025 and 1.53% for Q1 2025.